DLBCL represents one of the most common and heterogeneous forms of lymphoma, marked by its origin in B cells—white blood cells pivotal to generating antibodies and mounting immune responses. Despite advances in treatment, a significant portion of patients face poor prognoses due to these cancers’ resistance to standard chemotherapies and immunotherapies. The identification of Mann-type DLBCL centers around the presence of a distinct sugar molecule, mannose, expressed on the B-cell receptor surface of these cancerous cells. This sugar is not commonly abundant on healthy human cells, yet its presence profoundly influences the cancer’s behavior.

The University of Southampton team, in collaboration with scientists from Canada and the United States, conducted a comprehensive analysis involving data from 595 patients diagnosed with DLBCL. They cross-examined two robust datasets drawn from the BC Cancer Agency and the National Cancer Institute. Their investigational approach focused on detecting oligomannose-type glycans—complex carbohydrate structures consisting predominantly of mannose residues—on the lymphoma cells’ receptors. Astonishingly, approximately one-third of these DLBCL cases featured cells laden with these mannose-enriched structures, a hallmark that was further isolated as the defining trait of the new subtype.

From a biochemical perspective, the presence of mannose on B-cell receptors triggers signaling cascades that enhance lymphoma cell survival and proliferation. This aberrant glycosylation pattern provides a survival advantage to malignant cells, allowing them to evade apoptotic pathways and resist conventional anti-cancer drugs. Such resistance compounds clinical management challenges, as these cells exhibit aggressive growth kinetics and diminished responsiveness to treatments currently considered standard-of-care, often culminating in poorer patient outcomes.

The discovery that these mannose structures critically drive the pathophysiology of this DLBCL subset is particularly striking because carbohydrates have traditionally been underappreciated for their roles in tumor biology. Professor Max Crispin, a co-author from the University of Southampton’s Institute for Life Sciences, asserts that this work highlights how glycobiology—an interdisciplinary field exploring sugar molecules and their roles in cellular function—can unlock novel cancer mechanisms that were previously obscure. Identifying this glycan signature could therefore not only refine diagnostics but also open avenues for targeted drug development specifically disrupting the mannose-mediated pathways.

Clinically, the implications of this research are profound. The ability to classify and diagnose Mann-type DLBCL through conventional laboratory assays means physicians can more readily recognize patients who may require tailored treatment regimens. This clarity in classification sets the stage for personalized medicine interventions, where therapies are adapted to the intricacies of the tumor’s molecular profile rather than employing one-size-fits-all chemotherapy protocols. It marks an important step towards precision oncology, enabling better prognosis predictions and improved management strategies.

Technologically, the researchers utilized advanced data-analysis techniques combining clinical data with molecular profiling to delineate this subgroup. Such integration of large-scale patient cohorts and molecular biomarkers exemplifies the modern approach to cancer research, leveraging bioinformatics and multi-omics data to identify distinctive tumor phenotypes. The methodology employed demonstrates the power of harnessing statistical analyses with biochemical assays to unravel the heterogeneity obstructing progress in hematological malignancies.

Moreover, the discovery of the mannose-driven mechanism emphasizes the need to consider carbohydrate modifications as therapeutic targets. Inhibitors designed to interfere with mannose binding or its downstream signaling pathways could provide novel therapeutic modalities for patients with Mann-type DLBCL. This could shift treatment paradigms away from broadly cytotoxic agents towards precision-targeted molecules, potentially reducing adverse effects and enhancing treatment efficacy.

The study, recently published in the esteemed journal Blood, represents a significant leap forward in hematological cancer research. By elucidating the origin, diagnosis, and prognostic implications of oligomannose-type DLBCL, the researchers have laid a foundation upon which future studies can build more effective interventions. The interdisciplinary nature of the work—melding molecular biology, clinical oncology, and glycobiology—reflects a trend towards holistic understanding of cancer that transcends traditional boundaries.

Finally, this research underscores the vital importance of international collaboration in tackling complex diseases. Joined by teams from British Columbia’s BC Cancer Agency and Simon Fraser University, the effort exemplifies how pooling expertise and resources accelerates discoveries that might otherwise remain elusive. As the field moves forward, it is clear that these findings will stimulate further research aimed at developing mannose-targeted therapies and better diagnostic tools that ultimately improve survival and quality of life for patients afflicted with this aggressive lymphoma.

Subject of Research: People

Article Title: The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma

News Publication Date: 4-Sep-2025

Web References:
https://doi.org/10.1182/blood.2025029163

References:
Forconi, F., Crispin, M., et al. (2025). The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma. Blood. DOI: 10.1182/blood.2025029163.

Keywords: Cancer cells, Lymphoma

Chemotherapy remains a cornerstone of cancer treatment, yet its efficacy is frequently undermined by tumours’ ability to resist and evade therapeutic attack. Central to this resistance is the presence of tumour-associated macrophages (TAMs), a subset of immune cells that infiltrate tumour microenvironments, particularly clustering around tumour vasculature. These macrophages serve as immunological gatekeepers, creating a fortress-like barrier that prevents beneficial immune cells from penetrating tumours and supporting chemotherapy’s effectiveness.

The team from King’s College London has identified a critical protein produced by these macrophages—heme oxygenase-1 (HO-1)—which plays a pivotal role in this immune evasion strategy. HO-1 catalyzes the degradation of heme into biliverdin, iron ions, and carbon monoxide, exerting potent anti-inflammatory and cytoprotective effects within the tumour milieu. By leveraging this enzymatic function, the macrophages effectively shield cancer cells from immune-mediated destruction as well as the cytotoxic effects of chemotherapeutic agents.

To disrupt this protective shield, researchers engineered a small molecule inhibitor named KCL-HO-1i, designed specifically to inhibit HO-1 activity. The targeted inhibition of HO-1 undermines the macrophages’ ability to protect tumour cells, thereby restoring immune surveillance and enhancing chemotherapy efficacy. This strategic targeting represents an innovative angle in tumour immunotherapy, focusing on the tumour microenvironment rather than directly attacking cancer cells.

Professor James Arnold, leading the Tumour Immunology Group at King’s College London, emphasizes the significance of this approach: “Our discovery reveals that HO-1 expression in tumour-associated macrophages is a key factor limiting chemotherapy effectiveness. KCL-HO-1i enables us to modify the tumour microenvironment, facilitating the infiltration of immune effector cells and enhancing drug delivery, which collectively translate into improved tumour suppression, even in previously resistant cases.”

Remarkably, KCL-HO-1i presents a patient-friendly mode of administration. Unlike many cancer therapeutics that necessitate frequent hospital visits and invasive delivery methods, this drug is formulated as an oral tablet. Patients can conveniently take KCL-HO-1i at home during periods between chemotherapy sessions, greatly easing treatment burdens and improving adherence without compromising therapeutic outcomes.

The preclinical data supporting KCL-HO-1i’s potential are compelling. Utilizing robust mouse models of breast cancer, funded by Cancer Research UK and the Medical Research Council, the researchers demonstrated that combining KCL-HO-1i with standard chemotherapies significantly enhanced tumour regression across diverse chemotherapy regimens. These findings strongly suggest the drug’s utility may extend beyond breast cancer to a broad spectrum of solid tumours, magnifying its clinical impact.

Professor James Spicer, an authority in Experimental Cancer Medicine at King’s College London, remarks, “This drug represents a vital adjunct to current chemotherapy protocols. Our research unmasked one of the tumour’s stealth mechanisms and offered a tangible strategy to overcome it. We are eager to advance KCL-HO-1i into clinical trials to validate its safety and efficacy in patients, potentially transforming cancer care paradigms.”

Supporting this translational endeavor, Professor Miraz Rahman, Professor of Medicinal Chemistry, highlights the interdisciplinary collaboration underpinning this success. “Bridging immunology, chemistry, and clinical oncology enabled us to swiftly move from molecular target identification to drug development. Should clinical trials confirm preclinical promise, KCL-HO-1i could become an indispensable co-therapy, augmenting the effectiveness of existing cancer treatments and potentially reducing reliance on more aggressive therapeutic approaches,” he explains.

Experts beyond King’s College London echo excitement about this novel strategy. Tanya Hollands, Research Information Manager at Cancer Research UK, underscores the importance of optimizing existing treatments through rational combinations. “By pairing new agents like KCL-HO-1i with established chemotherapies, we may accelerate delivery of improved care, leveraging previous clinical experience while mitigating risk. This drug exemplifies the potential of precision medicine to refine and enhance conventional cancer therapy.”

Critical to the drug’s mechanism is reprogramming the tumour microenvironment from an immunosuppressive state to one conducive to immune activation and drug penetration. This reprogramming involves not only inhibiting HO-1 but also diminishing the production of immunosuppressive metabolites and signaling molecules. Subsequent immune infiltration and enhanced chemotherapy-induced cytotoxicity create a synergistic effect, profoundly influencing tumour control.

Looking ahead, the King’s College team anticipates that with appropriate funding, human clinical trials for KCL-HO-1i could commence within the next two years. These trials will probe not only safety and tolerability but also the drug’s capacity to overcome chemoresistance in diverse patient cohorts. Success in these studies would mark a pivotal advancement, becoming a new weapon in the oncologist’s arsenal against refractory cancers.

This discovery exemplifies the power of multidisciplinary research and innovative thinking in oncology. By targeting the cellular interplay within the tumour microenvironment rather than focusing solely on cancer cells, KCL-HO-1i represents a paradigm shift in therapeutic development. As the oncology community awaits clinical validation, this approach heralds a promising new chapter in the fight against resilient cancers, offering hope for improved survival and quality of life for patients worldwide.

Subject of Research: Development of a novel inhibitor targeting heme oxygenase-1 (HO-1) in tumour-associated macrophages to enhance chemotherapy efficacy.

Article Title: Not provided.

News Publication Date: Not provided.

Web References:

• Aethox Therapeutics

References:

• Full scientific article published in Science Translational Medicine (specific link not provided).

Image Credits:
Credit: King’s College London

Keywords:
Cancer, Cancer immunotherapy, Chemotherapy, Cancer medication, Medical treatments, Clinical medicine, Health and medicine, Life sciences, Pharmacology, Pharmaceuticals